∙Park W, Chawla A, O'Reilly EM. Pancreatic cancer: a review. Jama. 2021;326(9):851–62. This review article provides a comprehensive update on all aspects of pancreatic cancer and its management.

O’Kane GM, Knox JJ. Locally advanced pancreatic cancer: an emerging entity. Curr Probl Cancer. 2018;42(1):12–25.

Article  PubMed  Google Scholar 

∙∙Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340–7. This study discovered that LAPC patients who underwent neoadjuvant therpy and subsequent surgical resection had significantly longer median overall survival than those who did not undergo resection.

Hester CA, Katz MHG. Thumbprinting locally advanced pancreatic cancer: have we developed the optimal staging system? Ann Surg Oncol. 2021;28(11):5808–10.

Article  PubMed  Google Scholar 

Kwon W, Thomas A, Kluger MD. Irreversible electroporation of locally advanced pancreatic cancer. Semin Oncol. 2021;48(1):84–94.

Article  PubMed  Google Scholar 

Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, et al. Five-year actual overall survival in resected pancreatic cancer: a contemporary single-institution experience from a multidisciplinary perspective. Ann Surg Oncol. 2017;24(6):1722–30.

Article  PubMed  Google Scholar 

Springfeld C, Jäger D, Büchler MW, Strobel O, Hackert T, Palmer DH, et al. Chemotherapy for pancreatic cancer. La Presse Médicale. 2019;48(32):e159–74.

Article  PubMed  Google Scholar 

Reyngold M, Parikh P, Crane CH. Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. Radiat Oncol. 2019;14(1):95.

Article  PubMed  PubMed Central  Google Scholar 

Heerkens HD, van Vulpen M, Erickson B, Reerink O, Intven MP, van den Berg CA, et al. MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. Br J Radiol. 2018;91(1091):20170563.

Article  PubMed  PubMed Central  Google Scholar 

Morak MJ, Hermans JJ, Smeenk HG, Renders WM, Nuyttens JJ, Kazemier G, et al. Staging for locally advanced pancreatic cancer. Eur J Surg Oncol. 2009;35(9):963–8.

Article  CAS  PubMed  Google Scholar 

Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–20.

Article  PubMed  PubMed Central  Google Scholar 

Wang W, Shpaner A, Krishna SG, Ross WA, Bhutani MS, Tamm EP, et al. Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. Gastrointest Endosc. 2013;78(1):73–80.

Article  PubMed  Google Scholar 

Ghidini M, Vuozzo M, Galassi B, Mapelli P, Ceccarossi V, Caccamo L, et al. The role of positron emission tomography/computed tomography (PET/CT) for staging and disease response assessment in localized and locally advanced pancreatic cancer. Cancers (Basel). 2021;13(16):4155.

Article  CAS  PubMed  Google Scholar 

Yeh R, Dercle L, Garg I, Wang ZJ, Hough DM, Goenka AH. The Role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma. Abdominal Radiology. 2018;43(2):415–34.

Article  PubMed  Google Scholar 

∙∙NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Pancreatic Adenocarcinoma NCCN.org2022 [updated February 24, 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf. The most up to date guidelines from the NCCN on pancreatic adenocarcinoma.

∙Gemenetzis G, Blair AB, Nagai M, Groot VP, Ding D, Javed AA, et al. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2022;29(1):401–14. This article proposes a stratification system to evaluate the probability of eventual surgical resection in LAPC patients after initial therapy.

Loveday BPT, Lipton L, Thomson BN. Pancreatic cancer: an update on diagnosis and management. Aust J Gen Pract. 2019;48(12):826–31.

Article  PubMed  Google Scholar 

Lin X, Lin R, Lu F, Yang Y, Wang C, Fang H, et al. Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution. Langenbecks Arch Surg. 2021;406(7):2315–23.

Article  PubMed  Google Scholar 

Timmer FEF, Geboers B, Ruarus AH, Schouten EAC, Nieuwenhuizen S, Puijk RS, et al. Irreversible electroporation for locally advanced pancreatic cancer. Techniques Vasc Interventional Radiol. 2020;23(2):100675.

Article  Google Scholar 

∙Kim RY, Evans DB, Christians KK. Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. Hepatobiliary Surg Nutr. 2020;9(4):497–500. This paper outlines the use of CT imaging criteria to differentiate LAPC patients into two groups during staging to allow for better prediction of treatment success and overall survival.

∙Fromer MW, Hawthorne J, Philips P, Egger ME, Scoggins CR, McMasters KM, et al. An improved staging system for locally advanced pancreatic cancer: a critical need in the multidisciplinary era. Annals of Surgical Oncology. 2021;28(11):6201–10. This publication suggests a new staging system for pancreatic cancer in order to convey more actionable tumor descriptions.

Kinny-Köster B, Habib JR, Wolfgang CL, He J, Javed AA. Favorable tumor biology in locally advanced pancreatic cancer-beyond CA19-9. J Gastrointest Oncol. 2021;12(5):2484–94.

Article  PubMed  PubMed Central  Google Scholar 

Hyung J, Lee H, Jin H, Lee S, Lee HJ, Gong G, et al. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX. ESMO Open. 2022;7(3):100484.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu C, Cheng H, Luo G, Lu Y, Jin K, Guo M, et al. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer. Int J Oncol. 2017;51(2):686–94.

Article  CAS  PubMed  Google Scholar 

Hartlapp I, Valta-Seufzer D, Siveke JT, Algül H, Goekkurt E, Siegler G, et al. Prognostic and predictive value of CA 19–9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). ESMO Open. 2022;7(4):100552.

Article  CAS  PubMed  PubMed Central  Google Scholar 

∙Pietrasz D, Pécuchet N, Garlan F, Didelot A, Dubreuil O, Doat S, et al. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Clin Cancer Res. 2017;23(1):116–23. This study identifies ctDNA as a potential prognostic biokmarkers for LAPC patients which has been correlated with survival rates and chances of recurrence.

Caliez O, Pietrasz D, Ksontini F, Doat S, Simon JM, Vaillant JC, et al. Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma? Dig Liver Dis. 2022;54(10):1428–36.

Article  CAS  PubMed  Google Scholar 

Cheng H, Yang J, Fu X, Mao L, Chu X, Lu C, et al. Folate receptor-positive circulating tumor cells predict survival and recurrence patterns in patients undergoing resection for pancreatic cancer. Front Oncol. 2022;12:1012609.

Article  PubMed  PubMed Central  Google Scholar 

Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, et al. Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34(22):2654–68.

Article  PubMed  Google Scholar 

Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48.

Article  PubMed  Google Scholar 

Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17(6):801–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu CP, Shi J, Chen YX, Xie WF, Lin Y. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol. 2011;99(2):108–13.

Article  CAS  PubMed  Google Scholar 

∙∙Matsumoto I, Kamei K, Omae K, Suzuki S, Matsuoka H, Mizuno N, et al. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. Pancreatology. 2019;19(2):296–301. This is one of the first studies to evaluate the efficacy and tolerability of FOLFIRINOX in LAPC specifically.

McIntyre CA, Cohen NA, Goldman DA, Gonen M, Sadot E, O’Reilly EM, et al. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. J Surg Oncol. 2022;125(3):425–36.

Article  PubMed  Google Scholar 

Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, et al. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol. 2020;5(3):285–94.

Article  PubMed  Google Scholar 

∙Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, et al. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(2):128–38. This phase 2 trial evaluated the efficacy and safety of a nab-paclitaxel plus gemcitabine followed by FOLFIRINOX as an induction chemotherapy regimen in LAPC.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545–57.

Article  CAS  PubMed  Google Scholar 

Brown TJ, Reiss KA. PARP inhibitors in pancreatic cancer. Cancer J. 2021;27(6):465–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

∙Alva-Ruiz R, Yohanathan L, Yonkus JA, Abdelrahman AM, Gregory LA, Halfdanarson TR, et al. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2022;29(3):1579–91. Chemotherapy switching in patients unresponsive to initial therapy may allow for a larger proportion of patients to undergo curative-intent resection after neoadjuvant chemotherapy.

Tiriac H, Belleau P, Engle DD, Plenker D, Deschênes A, Somerville TDD, et al. Organoid profiling identifies common responders to chemotherapy in pancreatic cancer. Cancer Discov. 2018;8(9):1112–29.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hewitt DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL, et al. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Ann Surg. 2022;275(1):45–53.

Article  PubMed  Google Scholar 

Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, et al. Pancreatic cancer and immunotherapy: a clinical overview. Cancers (Basel). 2021;13(16):4138.

Article  CAS  PubMed  Google Scholar 

Fietkau R, Ghadimi M, Grützmann R, Wittel UA, Jacobasch L, Uhl W, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial. J Clin Oncol. 2022;40(16_suppl):4008.

Article  Google Scholar 

Hammel P, Huguet F, van Laethem J-L, Goldstein D, Glimelius B, Artru P, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.